Patient-specific mRNA cleared a phase 3 trial, an Icelandic catalogue caught Parkinson's variants, and skull marrow mounted a local immune response
A personalized melanoma therapy cleared a late-stage trial. A graph of Icelandic haplotypes surfaced missed structural variants tied to Parkinson's, and researchers mapped local immune hubs inside mouse skull marrow.
Science··Night
Personalized mRNA
A therapy built from a patient's own tumour mutations extended recurrence-free survival in 1,137 people whose melanoma had been surgically removed. Trial participants were split 2:1, with one group receiving intismeran autogene at 1 mg every three weeks plus another drug, and the rest receiving the second drug alone. The combination also delayed metastasis without setting off new safety signals, but overall survival is still being followed and no hazard ratio has been released yet.[1]
Icelandic haplotypes
Adding 698 Icelandic haplotypes to a reference genome surfaced 51.41 million small variants that a single linear reference missed. When short reads from 57,630 Icelanders mapped against the expanded graph, the search yielded 98.96 million variants, which was 6.17 per cent more than the linear version found. The new structural variants appeared largely where reads mapped poorly, revealing pathogenic mutations connected to Parkinson's disease and homocystinuria.[2]
Skull marrow hubs
Mice deploy their first immune response to brain threats from lymph-node-like hubs inside their skull bone marrow. A team mapped a distinct group of T cells in these hubs that drive B cell activation, allowing them to survey antigens coming from the central nervous system. Those adaptive immune cells contributed to anti-tumour responses in mouse brain cancer models; if human skulls hold similar hubs, they could shape immune responses across neurological diseases, although the possibility that humans lack them entirely remains.[3]
